Vineet Laboratories Limited Cash Flow Conversion Efficiency
Vineet Laboratories Limited cash flow conversion efficiency. Based on the latest financial reports, Vineet Laboratories Limited (VINEETLAB) has a cash flow conversion efficiency ratio of 0.035x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs12.24 Million ≈ $132.37K USD) by net assets (Rs348.52 Million ≈ $3.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vineet Laboratories Limited (2020–2025)
Cash flow conversion efficiency of Vineet Laboratories Limited from 2020 to 2025. This chart illustrates how Vineet Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Vineet Laboratories Limited for real-time trading data and today's change.
Vineet Laboratories Limited Cash Flow Conversion Ratio Explained
Vineet Laboratories Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vineet Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vineet Laboratories Limited ranked by their cash flow conversion efficiency. Also see Vineet Laboratories Limited market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Imperial Pacific Ltd
AU:IPC
|
0.024x |
|
Fatfish Group Ltd
AU:FFG
|
0.106x |
|
Weha Transportasi Indonesia TBK
JK:WEHA
|
0.069x |
|
Infimer Ltd
TA:INFR
|
0.002x |
|
Conduit Holdings Ltd
LSE:CRE
|
0.160x |
|
THG Holdings PLC
LSE:THG
|
-0.128x |
|
Minrex Resources Ltd
AU:MRR
|
-0.060x |
|
Radiant Utama Interinsco Tbk
JK:RUIS
|
0.083x |
Annual Cash Flow Conversion Efficiency for Vineet Laboratories Limited (2020–2025)
The table below shows the annual cash flow conversion efficiency of Vineet Laboratories Limited from 2020 to 2025. Review VINEETLAB cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs146.48 Million ≈ $1.58 Million |
Rs114.91 Million ≈ $1.24 Million |
0.784x | +512.06% |
| 2024-03-31 | Rs347.24 Million ≈ $3.76 Million |
Rs-66.11 Million ≈ $-714.94K |
-0.190x | +33.31% |
| 2023-03-31 | Rs336.83 Million ≈ $3.64 Million |
Rs-96.16 Million ≈ $-1.04 Million |
-0.285x | -222.92% |
| 2022-03-31 | Rs332.18 Million ≈ $3.59 Million |
Rs77.15 Million ≈ $834.34K |
0.232x | +170.95% |
| 2021-03-31 | Rs266.15 Million ≈ $2.88 Million |
Rs-87.12 Million ≈ $-942.20K |
-0.327x | -4160.69% |
| 2020-03-31 | Rs3.99 Million ≈ $43.14K |
Rs-30.65K ≈ $-331.44 |
-0.008x | -- |
About Vineet Laboratories Limited
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl… Read more